title: Ceftazidime treatment of chronic Pseudomonas infection in patients with cystic fibrosis.
abstract: Twenty-one patients with cystic fibrosis (CF), aged 1-18 years, with chronic lower respiratory tract infection caused by Pseudomonas aeruginosa, received 38 treatment courses of ceftazidime of 10-14 days duration. A favorable clinical response was observed in 28 of the 38 treatment courses. The minimal inhibitory concentration values of ceftazidime for the Pseudomonas isolates were concentrated around 0.5-1.0 mg/l, although a wide range of sensitivities was found (less than 0.03-32 mg/l). P. aeruginosa was eliminated after five treatment courses, but recurred after 1 month in four of these patients. The organism was permanently eradicated in one patient until his death 8 months later. Ceftazidime was well tolerated. The doses used in this study (50 mg/kg body weight i.v. twice daily) should probably be increased in order to achieve better microbiological response.
authors.affiliation: Department of Pediatrics, Gade Institute, Haukeland Hospital, Bergen, Norway.
authors.forename: G
authors.initials: G
authors.lastname: Fluge
authors.forename: A
authors.initials: A
authors.lastname: Digranes
authors.forename: H
authors.initials: H
authors.lastname: Michalsen
authors.forename: T
authors.initials: T
authors.lastname: Stiris
authors.forename: T
authors.initials: T
authors.lastname: Bergan
authors.forename: E K
authors.initials: EK
authors.lastname: Qvigstad
mesh_terms: D000293:Adolescent; D002442:Ceftazidime / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002908:Chronic Disease; D003550:Cystic Fibrosis / Q000150:complications*; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D011552:Pseudomonas Infections / Q000150:complications / Q000188:drug therapy*; D012141:Respiratory Tract Infections / Q000150:complications / Q000188:drug therapy*
chemical_list: D002442:Ceftazidime